DDInter41 DDInter150
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} (Compound) resembles {v} (Compound) Adenine
Adenine {u} (Compound) resembles {v} (Compound) Azathioprine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is bound by {v} (Compound) Azathioprine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) upregulates {v} (Gene) GTPBP8
GTPBP8 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Alemtuzumab {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Alemtuzumab {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) causes {v} (Side Effect) Toxic epidermal necrolysis
Toxic epidermal necrolysis {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Betamethasone {u} (Compound) upregulates {v} (Gene) MRPL12
MRPL12 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) resembles Adenine (Compound) and Adenine (Compound) resembles Azathioprine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is bound by Azathioprine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Azathioprine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Azathioprine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) upregulates GTPBP8 (Gene) and GTPBP8 (Gene) is upregulated by Azathioprine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is downregulated by Azathioprine (Compound)
Alemtuzumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Alemtuzumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Azathioprine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) upregulates MRPL12 (Gene) and MRPL12 (Gene) is downregulated by Azathioprine (Compound)